有针对性的下一代测序改善了克拉米迪亚菌群 (Chlamydia psittaci) 肺炎的诊断和抗菌管理
Yiting Yao1, Yanan Lai1, Qiong Wu2
1Department of Laboratory Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
概括
针对性下一代测序 (tNGS) 改善了克拉米迪亚肺炎 (CPP) 的诊断,使有效的抗菌药物管理成为可能. 奎诺隆在经验性治疗CPP方面非常有效.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 肺部病理学 肺部病理学
背景情况:
- 冠状病毒肺炎 (CPP) 由于非特异性症状,往往被诊断不足.
- 早期和准确的诊断对于有效的治疗和预防并发症至关重要.
研究的目的:
- 评估针对性下一代测序 (tNGS) 的临床实用性,用于诊断CPP.
- 为了评估经验性诺隆治疗在CPP患者的疗效.
- 探索CPP严重程度与共感染之间的关系.
主要方法:
- 对35名通过呼吸器样本的tNGS诊断的CPP患者进行了回顾性队列研究.
- 分析临床数据,实验室发现,成像和治疗结果.
- 严重和不严重的CPP病例之间的统计比较.
主要成果:
- tNGS促进了诊断,入院后的中位延迟为4天.
- 在CPP患者中观察到中性粒细胞比率,D-二聚体,CRP和ESR的升高.
- 严重的CPP病例显示CRP和prokalcitonin较高,多微生物共感染增加.
- 在60%的患者中发生了tNGS引导的治疗调整,导致97.1%的临床康复.
结论:
- tNGS显著改善了早期CPP诊断和抗菌药物治疗选择.
- 奎诺隆是CPP的有效实证药物.
- 严重的CPP与多微生物共感染有关,强调需要广泛的病原体查.
相关概念视频
Next-generation Sequencing
98.8K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
98.8K
Bacterial Phylum Chlamydiae
591
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
591
Antimicrobial Effectiveness
1.0K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.0K
Pneumonia I: Introduction
929
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
929
Pneumonia II: Pathophysiology
3.1K
The pathophysiology of pneumonia involves the following steps:
3.1K
Antimicrobial Proteins
14.5K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
14.5K


